ANDA 91436, held by Baxter Hlthcare Corp. Levofloxacin.
As of Nov 16, 2026, ANDA 91436 (Levofloxacin), held by Baxter Hlthcare Corp, was first approved by FDA on Jun 5, 2013, with 8 approved supplements and 0 published complete response letters.
Levofloxacin Injection is indicated for the treatment of adults (≥18 years of age) with mild, moderate, and severe infections caused by susceptible isolates of the designated microorganisms in the conditions listed in this section. Levofloxacin Injection is indicated when intravenous administration offers a route of administration advantageous to the patient (e.g., patient cannot tolerate an oral dosage form). Levofloxacin is a fluoroquinolone antibacterial indicated in adults (≥18 years of age) with infections caused by designated, susceptible bacteria ( 1, 12.4 ).
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jun 5, 2013 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| LevofloxacinEQ 500MG/20ML (EQ 25MG/ML) · injectable;injection | Levofloxacin | Discontinued |
| Sep 20, 2024 | Supplement 14Labeling · Standard review | Approved | None posted |
| May 6, 2019 | Supplement 9Labeling · Standard review | Approved | None posted |
| May 6, 2019 | Supplement 10Labeling · Standard review | Approved | None posted |
| Oct 18, 2018 | Supplement 8Labeling · Standard review | Approved | None posted |
| Oct 15, 2018 | Supplement 4Labeling · Standard review | Approved | None posted |
| Oct 15, 2018 | Supplement 7Labeling · Standard review | Approved | None posted |
| Sep 23, 2014 | Supplement 1Labeling · Standard review | Approved | None posted |
| Sep 23, 2014 | Supplement 3Labeling · Standard review | Approved | None posted |
| Jun 5, 2013 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters